Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and markets brand-name and generic pharmaceuticals and cell therapy platforms for cancer patients. The company is headquartered in Wexford, Pennsylvania.
52W High
$14.70
52W Low
$2.31
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
-0.56
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-0.64
EV/Revenue (<3 favorable)
218.14
P/S (TTM) (<3 favorable)
224.41
P/B (<3 favorable)
9.70
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
13.50%
Institutions (25–75% balanced)
3.03%
Shares Outstanding
4,820,300
Float
4,198,200
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
263,560
Gross Profit (TTM)
173,240
EPS (TTM)
-6.87
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-22.53%
ROE (TTM) (>15% strong)
-3.72%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
15.64
Momentum
Bearish momentumValue
0.2850
Previous
0.2685
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025